Kwality Pharmaceuticals Ltd — Board Meeting, 11-08-2025: Board Meeting

Kwality Pharmaceuticals reported a strong Q1 FY26. Consolidated revenue jumped 39.8% year-on-year to X111.8 crore, driven by increased sales of registered products in key international markets. EBITDA grew 39% to X24.6 crore, with margins stable at 22%. Net profit surged 43% to X11.9 crore. Operational highlights include a successful Zimbabwe regulatory audit and new product registrations. An EU-GMP audit for manufacturing facilities is scheduled for October, and a WHO-GMP inspection for the biologics facility (Erythropoietin) is planned later this year, along with production expansion, supporting the X500 crore FY26 revenue target.